52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein Interaction.
Janssen Research and Development
Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonists.
Janssen Research and Development
Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes.
Janssen Research and Development
Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Janssen Research and Development
Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Janssen Research and Development
The discovery and preclinical characterization of 6-chloro-N-(2-(4,4-difluoropiperidin-1-yl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinoline-5-carboxamide based P2X7 antagonists.
Janssen Research and Development
Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.
Janssen Research and Development
Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists.
Janssen Research and Development
Identification and SAR of Glycine Benzamides as Potent Agonists for the GPR139 Receptor.
Janssen Research and Development
Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
Janssen Research and Development
Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists.
Janssen Research and Development
Diaminopyrimidines, diaminopyridines and diaminopyridazines as histamine H4 receptor modulators.
Janssen Research and Development
The effect of pK(a) on pyrimidine/pyridine-derived histamine H4 ligands.
Janssen Research and Development
The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2.
Janssen Research and Development
Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H4 receptor antagonists.
Janssen Research and Development
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Janssen Research and Development
Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.
Janssen Research and Development
Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
Janssen Research and Development
Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists.
Janssen Research and Development
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Janssen Research and Development
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
Janssen Research and Development
The discovery of potent selective NPY Y(2) antagonists.
Janssen Research and Development
A thiocarbamate inhibitor of endothelial lipase raises HDL cholesterol levels in mice.
Janssen Research and Development
Arylglycine derivatives as potent transient receptor potential melastatin 8 (TRPM8) antagonists.
Janssen Research and Development
Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists.
Janssen Research and Development
Pyrazole-based arylalkyne cathepsin S inhibitors. Part III: modification of P4 region.
Janssen Research and Development
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.
Janssen Research and Development
Identification of benzofuran central cores for the inhibition of leukotriene A(4) hydrolase.
Janssen Research and Development
Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.
Janssen Research and Development
Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites.
Janssen Research and Development
Azabenzthiazole inhibitors of leukotriene A4 hydrolase.
Janssen Research and Development
Design and characterization of optimized adenosine A2A/A1 receptor antagonists for the treatment of Parkinson's disease.
Janssen Research and Development
Identification of a duald OR antagonist/µ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).
Janssen Research and Development
Structure-Based Optimization of Selective and Brain Penetrant CK1δ Inhibitors for the Treatment of Circadian Disruptions.
Janssen Research and Development
Discovery of Acyl-Indole Derivatives as Pan-Serotype Dengue Virus NS4B Inhibitors.
Janssen Research and Development
-Heterocyclic 3-Pyridyl Carboxamide Inhibitors of DHODH for the Treatment of Acute Myelogenous Leukemia.
Janssen Research and Development
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
Janssen Research and Development
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
Janssen Research and Development
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
Janssen Research and Development
Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease.
Janssen Research and Development
Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors.
Janssen Research and Development
Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Janssen Research and Development
Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes.
Janssen Research and Development
Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
Janssen Research and Development
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.
Janssen Research and Development
Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists.
Janssen Research and Development
4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.
Janssen Research and Development